Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?
Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.
Cuculi
F
F
The John Radcliffe, Headley Way, Oxford OX3 9DU, UK.
Lim
C C S
CC
Banning
A P
AP
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006335:Heart Injuries / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D015415:Biomarkers; D002316:Cardiotonic Agents; D010975:Platelet Aggregation Inhibitors